secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vyome Holdings, Inc (HIND)
CIK:        0001427570
Form:       8-K
Filed at:   2023-08-07T23:59:59+00:00
Accession:  0001558370-23-013626
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ReShape Lifesciences Q2 revenue down $0.6M YoY to $2.3M; operating expenses cut 53%
--------------------------------------------------------------------------------

- Revenue $2.3M (-$0.6M vs Q2 2022); gross margin 53.0% vs 65.1%.
- Non-GAAP adjusted EBITDA loss improved to $3.7M from $7.8M a year ago.
- Cash $4.7M, debt-free; completed $2.5M registered direct offering in April.
- Filed PMA supplement for Lap-Band 2.0; expects FDA feedback by year-end or early 2024.
- Signed Hive preferred partner AI SMS platform; consultations up 107% at select accounts.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1427570/000155837023013626/0001558370-23-013626-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1427570/000155837023013626/rsls-20230807x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-013626

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer